Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for FLNA.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2000. Start Trial.
Date Value
June 30, 2026 -0.016M
March 31, 2026 -0.051M
December 31, 2025 -0.329M
September 30, 2025 0.00
June 30, 2025 0.00
March 31, 2025 0.09M
December 31, 2024 0.918M
September 30, 2024 0.00
June 30, 2024 101.39M
March 31, 2024 22.16M
December 31, 2023 1.143M
September 30, 2023 0.464M
June 30, 2023 0.889M
March 31, 2023 0.064M
December 31, 2022 47.34M
September 30, 2022 0.136M
June 30, 2022 0.119M
March 31, 2022 0.211M
December 31, 2021 0.00
September 30, 2021 0.075M
June 30, 2021 1.274M
March 31, 2021 190.99M
December 31, 2020 70.61M
September 30, 2020 0.991M
June 30, 2020 0.236M
Date Value
March 31, 2020 3.613M
December 31, 2019 5.866M
September 30, 2019 0.00
June 30, 2019 0.00
March 31, 2019 -0.06M
December 31, 2018 -0.072M
September 30, 2018 12.27M
June 30, 2018 0.00
March 31, 2018 1.898M
December 31, 2017 0.00
September 30, 2017 0.00
June 30, 2017 0.00
March 31, 2017 0.00
December 31, 2016 -0.024M
September 30, 2016 0.00
June 30, 2016 -0.214M
March 31, 2016 -0.046M
December 31, 2015 -0.046M
September 30, 2015 0.00
June 30, 2015 0.00
March 31, 2015 0.00
December 31, 2014 0.00
September 30, 2014 0.00
June 30, 2014 0.313M
March 31, 2014 0.066M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
CorMedix, Inc. -6.894M
Eloxx Pharmaceuticals, Inc. 60.39M
Cannabis Global, Inc. 0.00
Breakthrough Chemistry, Inc. 0.00
BioStem Technologies, Inc. -1.146M